-
About UsWe are a company specializing in the research, development, and production of pharmaceutical and functional chemicals, dedicated to delivering innovative and high-quality products.
-
Main BusinessOur core focus is on the research and production of pharmaceutical chemicals and related products.
-
ProductsWe specialize in the technological breakthroughs, production, and sales of high-value specialty active pharmaceutical ingredients, small molecule chemical drugs, and pharmaceutical intermediates.
-
ESGPlacing a strong emphasis on sustainable development and continuously improve our quality management system, we actively implement these principles in our production processes and uphold our corporate social responsibility.
-
Join UsFind the job you’re suited to. Jingyu Group urgently needs passionate individuals like you who love pharmaceuticals and chemistry to join us!
About Us
Business saves lives, business defines innovation.
Company Overview
Beijing Whale Technology Corporation Ltd.
Jingyu Group is a conglomerate focused on the research and production of pharmaceutical chemicals. With a development strategy spanning from specialty active pharmaceutical ingredients to challenging generic drugs and innovative formulations, the company has nearly 400 employees. It has obtained certifications as a high-tech enterprise, an innovative small and medium-sized enterprise, and ISO9001 quality system certification. Over the past two years, the company has completed Series A and Series B financing rounds, and is preparing for an IPO within the next 2-3 years.
Jingyu Group has an organic synthesis research institute and a formulation research institute in Beijing, as well as three production bases in Gansu Province. Its main production includes raw materials and pharmaceutical intermediates for diabetes, cardiovascular, antiviral, and psychiatric drugs. The company is known as a high-quality supplier in the domestic pharmaceutical industry and has established a presence in international markets such as Europe, the United States, Japan, Korea, and the Middle East. Jingyu Group has obtained four invention patents and has submitted nearly 20 patent applications to the National Patent Office, demonstrating its research and development capabilities, long-term investment in innovation, and commitment to intellectual property rights.
Furthermore, to address the bottleneck in innovative formulations and excipients in China, in 2022, Jingyu Group successfully invested in Demarlik, a well-known German pharmaceutical company. Its core technology platform based on semi-fluorinated alkane dramatically improves the permeation efficiency of insoluble drugs by more than 50 times, representing a significant breakthrough in transdermal therapeutic system and filling the gap in this field domestically.
Founded in
National Patents
Cumulative Financing
Staff Size
Corporate Culture
Company Vision
To build a world-class and China's leading pharmaceutical and chemical industry group
Company Mission
Enhancing the System Capability of China's Pharmaceutical Chemical Industry
Company Philosophy
Business saves lives, business defines innovation
Company Value
People oriented and self driven; Logical thinking and scientific supremacy
Company Strategy
Building an SFA innovative transdermal drug delivery technology platform based on the industrialization capability of pharmaceutical chemistry, research and development, production
Company LOGO
Jing Yu is the Chinese pronunciation of whale, a kind and powerful creature;
The tail of a whale forms a fan shape, with dispersed branches and gathered foundation. It symbolize the diversification of the group and the cohesion of moving forward together with unity; The logo resembles a water droplet entering water, representing the concept of "embracing all rivers" or inclusiveness. The "8" branches on top symbolize good luck in Chinese culture and also resemble the infinity symbol "♾️," representing infinite possibilities.
Development History
Enterprise Environment